Newly developed antidote successfully reversed anti-clotting medication dabigatran

For the first time, an antidote developed specifically for dabigatran successfully reversed the effects of the anti-clotting medication in healthy volunteers, according to research presented at the American Heart Association's Scientific Sessions 2013.

New oral anti-clotting medications such as dabigatran (Pradaxa) are easier to take than warfarin. However, up until now, there have been no specific antidotes available to reverse the effects of these new anti-clotting medications when managing life-threatening bleeding or performing emergency surgery. This study shows some promise for an antidote for dabigatran.

Researchers developed an antibody fragment (Fab) that specifically binds dabigatran and prevents it from inhibiting .

Fab was given as 1 hour or 5-minute infusions to 145 healthy male volunteers. Immediate, complete and sustained reversal of dabigatran-induced anticoagulation was observed.

The antidote is still under development and is not yet approved for clinical use, researchers said.

Explore further

Haemodialysis works for reducing dabigatran levels: Implications for urgent use during bleeding or surgery

Citation: Newly developed antidote successfully reversed anti-clotting medication dabigatran (2013, November 18) retrieved 19 June 2021 from
This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.

Feedback to editors

User comments